Dapagliflozin (Forxiga ®) is a highly potent, reversible and selective sodiumglucose cotransporter2 inhibitor indied worldwide for the treatment of type 2 diabetes (T2D).In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) and as addon combination therapy (with other glucoselowering agents, including .